ArticleHistochemistry and cell biology2026
Oncogenic overexpression of kallikrein-related peptidase 7 is associated with the progression of thyroid cancer.
Article in Histochemistry and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mounting evidence suggests that the kallikrein-related peptidase family is dysregulated in thyroid cancer. However, previous analyses of kallikrein-related peptidase 7 (KLK7) expression patterns have yielded inconsistent results. In this study, KLK7 expression was examined in different histological types of thyroid cancer using immunohistochemistry. We found no detectable KLK7 immunoreactivity in the follicular epithelium of normal thyroid tissue or follicular adenomas. Weak KLK7 expression was observed in papillary (mean H-score 47) and follicular carcinomas (mean H-score 29), with moderate expression in anaplastic cancers (mean H-score 88; P for trend < 0.001). Membranous and cytoplasmic staining was validated using two independent antibodies and small interfering RNA (siRNA) knockdown controls. These observations were consistent with our bioinformatics analysis, which demonstrated that KLK7 was upregulated in less differentiated thyroid cancer and inversely correlated with thyroid differentiation scores. Knockdown of KLK7 expression through transfection with siRNA significantly impaired the viability, clonogenicity, and migratory abilities of thyroid cancer cells. This was accompanied by upregulation of E-cadherin and integrin-β1, along with elevated levels of the KLK7 substrates midkine and tenascin-C. Taken together, our results indicate that KLK7 is overexpressed in thyroid cancer and is linked to disease progression and dedifferentiation, partly by disrupting cell adhesion networks. KLK7 may therefore serve as a biomarker for aggressive thyroid cancer and a potential therapeutic target.
Indexed as
Identifiers
42017987What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.